This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment
by Zacks.com
PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.
Mersana Stock Spikes on Interim Data on Cancer Candidate
by Zacks Equity Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
Top Stock Reports for Alphabet, Visa & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V) and Bank of America (BAC).
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug
by Zacks Equity Research
Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
by Kinjel Shah
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
by Zacks Equity Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.
Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.
Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo in combination with Yervoy gets FDA nod for the first-line treatment of NSCLC patients.
Merck's (MRK) Keytruda Successful in Several Cancer Studies
by Zacks Equity Research
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
Roche Posts Positive Phase II Results on Immunotherapy Combo
by Zacks Equity Research
Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.
Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA
by Zacks Equity Research
Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) PARP inhibitor Lynparza as a first-line maintenance treatment for HRD-positive advanced ovarian cancer. The approval was based on data from the phase III PAOLA-1 study.
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
by Kinjel Shah
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
by Zacks Equity Research
Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.
Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y
by Zacks Equity Research
Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year.
Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus
by Zacks Equity Research
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.